Pasithea Therapeutics shares jumped more than 220% in early trading

Tiger Newspress2021-11-23

Pasithea Therapeutics shares jumped more than 220% in early trading after the company said its wholly-owned Pasithea Clinics subsidiary was approved to provide esketamine nasal spray Spravato for treatment-resistant depression in adults.

The company said it has begun offering the treatment in its Knightsbridge, London, location.

Pasithea said esketamine is safe and effective, but due to some risks associated with the drug, patients treated in outpatient settings must be enrolled in a specific program.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
27